drugset / Trial / NCT04169100

Novel Form of Acquired Long QT Syndrome

NCT04169100

NaSingle-groupOpen-labelPrevention

Summary

The goal of this study is to determine whether anti-Ro/SSA antibodies are associated with acquired QT prolongation in subjects with connective tissue disease. The investigators will investigate whether gender or race influence correlation between anti-Ro antibody status and prolonged QT interval and the role of inflammatory cytokines in association with anti-Ro antibodies and QT prolongation. The investigators propose to add an additional objective to test whether QT prolongation is reversible with moderate doses of prednisone in patients with QT interval greater than 500 msec.

Timeline

Start
2011-09-28
Primary completion
2024-03-31
Completion
2024-09-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Prednisone Other / unclassified 20 mg Oral